This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Positive Results Presented From Proof-of-Concept Phase II Clinical Trial Of Incyte's Oral JAK1 Inhibitor In Patients With Myelofibrosis

Incyte Corporation (Nasdaq: INCY) announced results of an interim analysis from a 12-week open-label, dose-escalation Phase II clinical trial involving more than 85 patients with intermediate or high-risk myelofibrosis (MF) for its proprietary oral JAK1 inhibitor, INCB39110. These results were presented today at the 2013 American Society of Hematology (ASH) Annual Meeting in New Orleans.

In this preliminary analysis of an ongoing Phase II trial that involved three doses (100 mg twice daily, 200 mg twice daily and 600 mg once daily), treatment with INCB39110 at doses of 200 mg twice daily and 600 mg once daily provided meaningful improvements in MF-related symptoms, including symptoms associated with splenomegaly. At week 12, 22.2 percent, 34.9 percent, and 50.0 percent of patients in the 100 mg twice daily, 200 mg twice daily, and 600 mg once daily dose groups, respectively, achieved at least a 50 percent improvement from baseline in their total symptom score (the primary endpoint); median percentage improvements from baseline at this time point were 28.5 percent, 45.8 percent, and 76.8 percent, respectively, across dose groups. Reductions in spleen volume were modest, with median percentage changes from baseline to week 12 of 5.0 percent, -14.1 percent, and -9.9 percent, respectively, across dose groups. The most common hematologic adverse events, regardless of causality, were anemia and thrombocytopenia, and the most common non-hematologic adverse events were fatigue, constipation and nausea. In comparison to JAK1/JAK2 inhibitors and JAK2 inhibitors, the findings from this analysis suggest that JAK1 inhibition may result in less myelosuppression. In patients not receiving post-baseline transfusions, mean hemoglobin levels in each dose group increased by week 2 and remained approximately 0.5 to 1.0 g/dL above baseline through week 12.

To access the presentation: ASH 2013 - Mascarenhas

“With the interim analysis of this trial combined with data from two other proof-of-concept trials in rheumatoid arthritis and psoriasis, we have a better understanding of JAK1 as a disease target, and we’re using this knowledge to focus the development of our broad portfolio of JAK1 inhibitors,” stated Richard S. Levy, M.D., Incyte’s Executive Vice President and Chief Drug Development and Medical Officer. “We are taking INCB39110, our most advanced JAK1 inhibitor, forward initially in solid tumors, starting with combinations that may not be as well-tolerated with a JAK1/JAK2 inhibitor as a result of the potential myelosuppressive effect of JAK2 inhibition.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $241.80 0.43%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs